Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

@article{Shen2005PatientspecificDO,
  title={Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.},
  author={Sui Shen and Andres Forero and Albert F Lobuglio and Hazel B. Breitz and Muhammad B Khazaeli and Darrell R Fisher and Wenquan Wang and Ruby F. Meredith},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2005},
  volume={46 4},
  pages={642-51}
}
UNLABELLED Pretargeted radioimmunotherapy (RIT) using CC49 fusion protein, comprised of CC49-(scFv)4 and streptavidin, in conjunction with 90Y/111In-DOTA-biotin (DOTA = dodecanetetraacetic acid) provides a new opportunity to improve efficacy by increasing the tumor-to-normal tissue dose ratio. To our knowledge, the patient-specific dosimetry of pretargeted 90Y/111In-DOTA-biotin after CC49 fusion protein in patients has not been reported previously. METHODS Nine patients received 3-step… CONTINUE READING
19 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…